Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CALM1 | P0DP23 | 2/20 | 0.50 |
| ▸ | CHKA | P35790 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7494593 | 0.86 | ALDH1A1 (0.54) | ALDH1A1TSHRCYP3A4MAPK1TDP1 | |
| SCHEMBL4405018 | 0.85 | ALDH1A1 (0.70) | ALDH1A1TSHRCYP3A4MAPK1TDP1 | |
| SCHEMBL7071417 | 0.83 | CHKA (0.53) | ALDH1A1TSHRCYP3A4MAPK1TDP1 | |
| SCHEMBL7075274 | 0.83 | CHKA (0.53) | ALDH1A1TSHRCYP3A4MAPK1TDP1 | |
| SCHEMBL5741268 | 0.83 | CHKA (0.53) | ALDH1A1TSHRCYP3A4MAPK1TDP1 | |
| SCHEMBL7072445 | 0.83 | CHKA (0.53) | ALDH1A1TSHRCYP3A4MAPK1TDP1 | |
| SCHEMBL696310 | 0.80 | ALDH1A1 (0.64) | ALDH1A1TSHRCYP3A4MAPK1TDP1 | |
| SCHEMBL6310153 | 0.80 | ALDH1A1 (0.64) | ALDH1A1TSHRCYP3A4MAPK1TDP1 | |
| SCHEMBL2745550 | 0.79 | GFER (0.42) | ALDH1A1TDP1ALOX15HSD17B10HRH3 | |
| SCHEMBL171763 | 0.78 | ALDH1A1 (0.61) | ALDH1A1TSHRCYP3A4MAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4769493-A | Process for producing tetrafluorophthalic acid | SDS BIOTECH K.K. (JP) | 1988-09-06 | — | — | US | claimed |
| EP-0259663-A1 | Process for producing tetrafluorophihalic acid | SDS Biotech K.K. (JP) | 1988-03-16 | — | — | EP | claimed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| US-20140039171-A1 | NOVEL MACROLIDE INTERMEDIATE AND NOVEL PRODUCTION PROCESS | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-02-06 | — | — | US | disclosed |
| EP-2682399-A1 | NOVEL MACROLIDE INTERMEDIATE AND NOVEL PRODUCTION PROCESS | Meiji Seika Pharma Co., Ltd. (JP) | 2014-01-08 | — | — | EP | disclosed |
| CN-103391944-A | Novel macrolide intermediate and novel production process | MEIJI SEIKA PHARMA CO LTD | 2013-11-13 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| CN-101255170-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-09-03 | — | — | CN | disclosed |
| CN-101172981-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-05-07 | — | — | CN | disclosed |
| CN-100366624-C | 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds | OTSUKA PHARMA CO LTD (JP) | 2008-02-06 | — | — | CN | disclosed |
| US-20030013663-A1 | 6-O-CARBAMOYL KETOLIDE ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-01-16 | — | — | US | disclosed |
| US-6472372-B1 | 6-O-Carbamoyl ketolide antibacterials | ORTHO-MCNEIL PHARMACEUTICALS, INC. | 2002-10-29 | — | — | US | disclosed |
| US-20020115620-A1 | 6-0-carbamoyl ketolide antibacterials | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-08-22 | — | — | US | disclosed |
| CN-1278816-A | 5, 11-dihydrodibenzo [ b, e ] [1,4] oxazepine * derivatives and pharmaceutical compositions containing the same | AJINOMOTO KK (JP) | 2001-01-03 | — | — | CN | disclosed |
| EP-0435503-B1 | Improvements in or relating to gylcopeptide derivatives | LILLY CO ELI (US) | 1999-05-06 | — | — | EP | disclosed |
| US-5591714-A | TREATING VANCOMYCIN RESISTANT ENTEROCOCCUS INFECTIONS WITH GLYCOPEPTIDE ANTIBIOTIC | ELI LILLY AND COMPANY (US) | 1997-01-07 | — | — | US | disclosed |
| EP-0435503-A1 | Improvements in or relating to gylcopeptide derivatives | ELI LILLY AND COMPANY (US) | 1991-07-03 | — | — | EP | disclosed |
| US-4769493-A | Process for producing tetrafluorophthalic acid | SDS BIOTECH K.K. (JP) | 1988-09-06 | — | — | US | disclosed |
| EP-0259663-A1 | Process for producing tetrafluorophihalic acid | SDS Biotech K.K. (JP) | 1988-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140039171-A1 | NOVEL MACROLIDE INTERMEDIATE AND NOVEL PRODUCTION PROCESS | MRPL21, PIGS, CYP51A1 | ALDH1A1 2227/4885TSHR 3419/4885CYP3A4 63/4885 |
| US-20030013663-A1 | 6-O-CARBAMOYL KETOLIDE ANTIBACTERIALS | Q6ZSR9, KDM4E, HK1 | ALDH1A1 3560/4885TSHR 3220/4885CYP3A4 1070/4885 |
| US-20020115620-A1 | 6-0-carbamoyl ketolide antibacterials | Q6ZSR9, HK1, KDM4E | ALDH1A1 3629/4885TSHR 3357/4885CYP3A4 1193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.